Lorazepam

Standard Drug Panel Inclusion

Lorazepam is included on standard 10-panel drug screens and extended benzodiazepine panels. However, lorazepam presents a known challenge for immunoassay-based screening. Unlike diazepam, which produces metabolites with strong antibody cross-reactivity, lorazepam is conjugated directly to glucuronide without producing intermediate metabolites. Some immunoassay platforms have reduced sensitivity to lorazepam glucuronide, and false-negative results are documented in the clinical literature. Enzymatic hydrolysis of the urine sample prior to testing significantly improves detection rates.

Urine Detection

After a single dose, lorazepam is detectable in urine for approximately 3 to 5 days. Chronic users may test positive for 1 to 2 weeks. The primary urinary analyte is lorazepam glucuronide. Without sample hydrolysis, some laboratories report detection rates as low as 50 to 70 percent for lorazepam at standard cutoff concentrations of 300 ng/mL. Hydrolysis converts the glucuronide back to free lorazepam, improving detection rates above 95 percent.

Blood and Serum Detection

Lorazepam is detectable in blood for 1 to 3 days. Therapeutic concentrations range from 50 to 240 ng/mL. Peak plasma concentrations are reached approximately 2 hours after oral administration. Blood testing is common in emergency department settings for suspected benzodiazepine overdose.

Hair Follicle Detection

Lorazepam can be detected in hair for up to 90 days, though incorporation rates into the hair shaft are lower than for more lipophilic benzodiazepines like diazepam. Analytical sensitivity below 5 pg/mg of hair is typically required.

Confirmatory Methods

LC-MS/MS is the gold standard for lorazepam confirmation, offering definitive identification and quantification. GC-MS can also confirm lorazepam but requires derivatization. The enzymatic hydrolysis step prior to extraction is critical for accurate results. Limits of detection for LC-MS/MS are typically 1 to 5 ng/mL.

Reagent Testing

Lorazepam shows a yellow-green response with the Zimmermann reagent and a green-brown color with Mandelin. These reactions are not specific enough to distinguish lorazepam from other benzodiazepines. Fentanyl test strips should be applied to any lorazepam obtained from unregulated sources.

The Cardinal Rule

NEVER combine lorazepam with alcohol, opioids, or other CNS depressants. This combination is responsible for the vast majority of benzodiazepine-related deaths. Even seemingly small amounts of alcohol combined with a therapeutic dose of lorazepam can cause dangerous respiratory depression.

Dosing Safety

• Keep a written dose log. Lorazepam causes anterograde amnesia. You may genuinely not remember whether you took your last dose. A physical log (written on paper next to the medication, not on your phone where you might not check it) prevents accidental double-dosing.
• Give extras to a trusted person. If you are using recreationally, hand any additional pills to a sober friend before you take your first dose. Your impaired, amnestic self will happily take more if they are accessible.
• Do not drive or operate machinery. Lorazepam impairs reaction time, coordination, and judgment even at therapeutic doses. These impairments persist longer than the subjective feeling of sedation.

Dependence and Withdrawal

• Physical dependence can develop within 2 to 4 weeks of daily use. This is not theoretical -- it is extremely common with any benzodiazepine taken daily.
• NEVER stop abruptly after regular use. Benzodiazepine withdrawal can cause seizures, psychosis, and death. This is not an exaggeration. Alcohol and benzodiazepines are among the very few drug classes where withdrawal itself can be fatal.
• Taper gradually under medical supervision. The Ashton Manual (benzo.org.uk) is the gold-standard resource for benzodiazepine tapering protocols. A typical taper involves switching to an equivalent dose of a long-acting benzodiazepine (diazepam) and reducing by 5-10% every 1-2 weeks.
• Tolerance develops rapidly. The anxiolytic effects diminish within days to weeks of regular use, leading to dose escalation. This is the beginning of a dependence cycle.

Avoid Daily Use

• Use as-needed, not on a schedule, if possible. The faster you develop tolerance, the faster you develop dependence. Limiting use to 2-3 times per week or less dramatically reduces dependence risk.
• Benzodiazepines are meant for short-term use. Most prescribing guidelines recommend no more than 2-4 weeks of continuous use. If you need long-term anxiety management, discuss alternatives with a doctor (SSRIs, buspirone, therapy).

Specific Risks

• Elderly patients: Increased sensitivity, increased fall risk, slower metabolism. Lower doses are essential.
• Pregnancy: Benzodiazepines cross the placenta and are associated with neonatal withdrawal syndrome and potential teratogenicity. Avoid use during pregnancy.
• Mixing with stimulants: Using benzodiazepines to "come down" from stimulants is a common pattern that accelerates dependence on both substances.

Acute Toxicity -- Lorazepam Alone

Benzodiazepines have a very wide therapeutic index when taken alone. The lethal dose of lorazepam in an otherwise healthy adult, without co-ingestants, is estimated to be many times the maximum therapeutic dose. Pure benzodiazepine overdoses rarely result in death in healthy individuals. Symptoms of isolated benzodiazepine overdose include deep sedation, confusion, slurred speech, ataxia, and mild respiratory depression.

Acute Toxicity -- In Combination

The safety profile changes dramatically when lorazepam is combined with other central nervous system (CNS) depressants:

• Alcohol: Synergistic respiratory depression. Lorazepam plus alcohol is one of the most common drug combinations seen in emergency departments and is frequently fatal.
• Opioids: Profoundly synergistic. The combination of benzodiazepines and opioids is a leading cause of drug overdose death in the United States and worldwide. Even therapeutic doses of each, when combined, can produce fatal respiratory arrest.
• Barbiturates and other sedatives: Additive or synergistic CNS depression.
• GHB/GBL: Extremely dangerous combination with steep dose-response for respiratory depression.

Long-Term Toxicity

• Cognitive impairment: Chronic benzodiazepine use is associated with impaired memory, attention, and processing speed. There is ongoing debate about whether these effects are fully reversible after cessation.
• Increased fall risk: Particularly in the elderly, where benzodiazepines are associated with hip fractures and other fall-related injuries.
• Paradoxical reactions: Long-term use can produce worsening anxiety, insomnia, irritability, and aggression -- the very symptoms the drug was prescribed to treat.
• Depression: Chronic use is associated with increased rates of depression.
• Dementia risk: Some epidemiological studies suggest an association between chronic benzodiazepine use and increased risk of dementia, though causality has not been established.

Internationally, lorazepam is a Schedule IV drug under the United Nations Convention on Psychotropic Substances.

• Austria: Lorazepam is legal for medical use under the AMG (Arzneimittelgesetz Österreich) and illegal when sold or possessed without a prescription under the SMG (Suchtmittelgesetz Österreich).

• Canada: Lorazepam is listed in Schedule IV of the Controlled Drugs and Substances Act in Canada.

• China:** Lorazepam is a controlled Class II psychotropic substances. Prescriptions for psychotropic substances in Class II are generally limited to a 7-day supply.

• Germany: Lorazepam is controlled under Anlage III BtMG (Narcotics Act, Schedule III) as of August 1, 1986. It can only be prescribed on a narcotic prescription form, except preparations which contain up to 2.5 mg lorazepam in each dosage form.

• New Zealand: Lorazepam is a Class C Controlled drug under the Misuse of Drugs Act 1975.

• Russia: Lorazepam is a Schedule III controlled substance since 2013.

• Switzerland: Lorazepam is a controlled substance specifically named under Verzeichnis B. Medicinal use is permitted.

• Turkey: Lorazepam is a 'green prescription' only substance and illegal when sold or possessed without a prescription.

• United Kingdom: Lorazepam is classified as a controlled substance and is listed under Schedule IV, Part I (CD Benz POM) of the Misuse of Drugs Regulations 2001, allowing possession with a valid prescription. The Misuse of Drugs Act 1971 makes it illegal to possess it without a prescription and, for such purposes, it is classified as a Class C drug.

• United States: Lorazepam is a Schedule IV drug under the Controlled Substances Act.

• Poland: Lorazepam is controlled under act of psychotropic substances list IV-P Group of "low potential for abuse" (with other benzodiazepines in this group). It's legal for medical, scientific and manufacturing purposes.

• Responsible use

• Psychoactive substance index

• Etizolam

• Benzodiazepines

• Depressants

• Volumetric liquid dosing

• Lorazepam (Wikipedia)

• Lorazepam (Erowid Vault)

• Lorazepam (Isomer Design)

• Lorazepam (DrugBank)

• Lorazepam (Drugs.com)

• Lorazepam (Drugs-Forum)